Rat Vitamin K1 ELISA Kit

Name: Rat Vitamin K1 ELISA Kit
SKU: DEIA-BJ2320
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

plasma, serum.

Species Reactivity

Rat

Detection Method

cELISA

Intended Use

Rat Vitamin K1 ELISA Kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of the Vitamin K1. This ELISA kit is for research use only, not for therapeutic or diagnostic applications.

Storage

The unopened kit can be stored at 2°C to 8°C through the expiration date. Once opened the kit can be stored at 2°C to 8°C for 1 month. Unused strips should be kept in a sealed bag with the desiccant provided to minimize exposure to damp air.

Precision

Intra-Assay CV (<10%); Inter-Assay CV (<10%)

Detection Range

250–5000 pg/ml

Sensitivity

Typically less than 1 pg/ml

Standard Curve

The following standard curve is an example only and should not be used to calculate results for tested samples. A new standard curve must be generated for each set of samples tested.

Citations

Have you cited DEIA-BJ2320 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico

CELL

Authors: Robbiani, Davide F.; Bozzacco, Leonia; Keeffe, Jennifer R.; Khouri, Ricardo; Olsen, Priscilla C.; Gazumyan, Anna; Schaefer-Babajew, Dennis; Avila-Rios, Santiago; Nogueira, Lilian; Patel, Roshni; Azzopardi, Stephanie A.; Uhl, Lion F. K.; Saeed, Mohsan; Sevilla-Reyes, Edgar E.; Agudelo, Marianna; Yao, Kai-Hui; Golijanin, Jovana; Gristick, Harry B.; Lee, Yu E.; Hurley, Arlene; Caskey, Marina; Pai, Joy; Oliveira, Thiago; Wunder, Elsio A., Jr.; Sacramento, Gielson; Nery, Nivison, Jr.; Orge, Cibele; Costa, Federico; Reis, Mitermayer G.; Thomas, Neena M.; Eisenreich, Thomas; Weinberger, Daniel M.; de Almeida, Antonio R. P.; West, Anthony P., Jr.; Rice, Charles M.; Bjorkman, Pamela J.; Reyes-Teran, Gustavo; Ko, Albert I.; MacDonald, Margaret R.; Nussenzweig, Michel C.

Abstract

Antibodies to Zika virus (ZIKV) can be protective. To examine the antibody response in individuals who develop high titers of anti-ZIKV antibodies, we screened cohorts in Brazil and Mexico for ZIKV envelope domain III (ZEDIII) binding and neutralization. We find that serologic reactivity to dengue 1 virus (DENV1) EDIII before ZIKV exposure is associated with increased ZIKV neutralizing titers after exposure. Antibody cloning shows that donors with high ZIKV neutralizing antibody titers have expanded clones of memory B cells that express the same immunoglobulin VH3-23/VK1-5 genes. These recurring antibodies cross-react with DENV1, but not other flaviviruses, neutralize both DENV1 and ZIKV, and protect mice against ZIKV challenge. Structural analyses reveal the mechanism of recognition of the ZEDIII lateral ridge by VH3-23/VK1-5 antibodies. Serologic testing shows that antibodies to this region correlate with serumneutralizing activity to ZIKV. Thus, high neutralizing responses to ZIKV are associated with pre-existing reactivity to DENV1 in humans.

Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy

THROMBOSIS RESEARCH

Authors: Hirai, Keita; Yamada, Yuto; Hayashi, Hideki; Tanaka, Masaki; Izumiya, Kohei; Suzuki, Masayuki; Yoshizawa, Misa; Moriwaki, Hideaki; Akimoto, Takehide; Tsuji, Daiki; Inoue, Kazuyuki; Itoh, Kunihiko

Abstract

Introduction: Warfarin is characterized by a large inter-individual variability in dosage requirement. This study aimed to analyze the contribution of the CYP4F2 genetic polymorphism and plasma vitamin K concentration on the warfarin pharmacodynamics in patients and to clarify the plasma vitamin K concentration affecting warfarin sensitivity index in rats. Materials and Methods: Genetic analyses of selected genes were performed and plasma concentrations of warfarin, vitamin K1 (VK1) and menaquinone-4 (MK-4) were measured in 217 Japanese patients. We also assessed the association of plasma VK1 and MK-4 concentrations with the warfarin sensitivity index (INR/Cp) in rats. Results: Patients with the CYP4F2 (rs2108622) TT genotype had significantly higher plasma VK1 and MK-4 concentrations than those with CC and CT genotypes. The multiple linear regression model including VKORC1, CYP4F2, and CYP2C9 genetic variants, age, and weight could explain 42% of the variability in warfarin dosage. The contribution of CYP4F2 polymorphism was estimated to be 2.2%. In contrast, plasma VK1 and MK-4 concentrations were not significantly associated with warfarin dosage in patients. Nevertheless, we were able to demonstrate that the warfarin sensitivity index was attenuated and negatively correlated with plasma VK1 concentration by the oral administration of VK1 in rats, as it resulted in a higher VK1 concentration than that in patients. Conclusions: The plasma VK1 and MK-4 concentrations are significantly influenced by CYP4F2 genetic polymorphism but not associated with warfarin therapy at the observed concentration in Japanese patients. The CYP4F2 polymorphism is poorly associated with inter-individual variability of warfarin dosage requirement. (C) 2015 Elsevier Ltd. All rights reserved.